The variant gambit: COVID-19’s next move
Open accessAbstract
More than a year after its emergence, COVID-19, the disease caused by SARS-CoV-2, continues to plague the world and dominate our daily lives. Even with the development of effective vaccines, this coronavirus pandemic continues to cause a fervor with the identification of major new variants hailing from the United Kingdom, South Africa, Brazil, and California. Coupled with worries over a distinct mink strain that has caused human infections and potential for further mutations, SARS-CoV-2 variants bring concerns for increased spread and escape from both vaccine and natural infection immunity. Here, we outline factors driving SARS-CoV-2 variant evolution, explore the potential impact of specific mutations, examine the risk of further mutations, and consider the experimental studies needed to understand the threat these variants pose. In this review, Plante et al. examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California). They focus on what factors contribute to variant emergence, mutations in and outside the spike protein, and studies needed to understand the impact of variants on infection, transmission, and vaccine efficacy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The T478K mutation is close to the E484K mutation that facilitates antibody escape.
“This mutation is close to the E484K mutation that facilitates antibody escape 13 .”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [13]
The “RBD variant changes” section associates E484K with immune escape from monoclonal antibodies and polyclonal sera. It does not mention T478K or establish that T478K is close to E484K (searched: T478K, residue 478, and proximity to E484K). (LLM, conf=0.85)
Experimental — accuracy not yet measuredThe only mutation within the ACE2 patch is at location 501, which increases the affinity of the RBD for ACE2 and is also involved in antibody escape.
“The only mutation within the ACE2 patch is at location 501, which increases the affinity of the RBD for ACE2 and is also involved in antibody escape 13 .”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [13]
The RBD variant changes section (page unavailable) says N501Y may improve ACE2 binding affinity, but presents this as a possibility rather than an established increase. It does not identify position 501 as the only mutation at the ACE2 interface: it describes a change at K417 that disrupts an interaction with ACE2. It also reports only marginal antibody-neutralization changes for N501Y, suggesting receptor binding rather than antibody escape as its main implication. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe D950N mutation maps to the trimer interface, suggesting it may contribute to regulation of spike protein dynamics, as shown for D614G.
“the D950N mutation mapped to the trimer interface (Extended Data Fig.4a), suggesting that this mutation may contribute to the regulation of spike protein dynamics, as shown for the D614G mutation 13”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · see citing works
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · see citing works
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611 · see citing works
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · see citing works
Self-citationSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works
Evasion of Type I Interferon by SARS-CoV-2
Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957 · see citing works
Self-citationN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901 · see citing works
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · see citing works
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743 · see citing works
Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725 · see citing works
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651 · see citing works
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647 · see citing works
Self-citationRecurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
McCarthy, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarthy, L. R., Bain, W. G., Haidar, G., & Duprex, W. P. (2021) · Science · doi:10.1126/science.abf6950 · Cited by 535 · see citing works
Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., et al. (2021) · Science · doi:10.1126/science.abe9728 · Cited by 488 · see citing works
Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2020) · doi:10.1101/2020.11.06.372037 · Cited by 135 · see citing works
SARS-CoV-2 escape <i>in vitro</i> from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451 · cited 1×
“This change may correspond with improved binding to ACE2 but has also been associated with immune escape from both monoclonal antibodies and polyclonal sera (Starr et al., 2021; Andreano et al., 2020; Weisblum et al., 2020).”
Background
Flagged first, then by citations
Research works printed but not linked: 33
- Cong Y. Ulasli M. Schepers H. Mauthe M. V'Kovski P. Kriegenburg F. Thiel V. De Haan C.A.M. Reggiori F. Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle J. Virol. 94 2020 e01925–19 PMC6997762 31776274
- Dinnon K.H. Leist S.R. Schäfer A. Edwards C.E. Martinez D.R. Montgomery S.A. West A. Yount B.L. Hou Y.J. Adams L.E. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures Nature 586 2020 560 566 32854108 PMC8034761
- Domingo E. Escarmís C. Lázaro E. Manrubia S.C. Quasispecies dynamics and RNA virus extinction Virus Res 107 2005 129 139 15649559
- Eurosurveillance editorial team Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update EURO Surveill 26 2021 PMC7848680 33478621
- Gómez-Carballa A. Bello X. Pardo-Seco J. Martinón-Torres F. Salas A. Mapping genome variation of SARS-CoV-2 worldwide highlights the impact of COVID-19 super-spreaders Genome Res 30 2020 1434 1448 32878977 PMC7605265
- Gordon D.E. Jang G.M. Bouhaddou M. Xu J. Obernier K. White K.M. O’Meara M.J. Rezelj V.V. Guo J.Z. Swaney D.L. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Nature 583 2020 459 468 32353859 PMC7431030
- Gu H. Chen Q. Yang G. He L. Fan H. Deng Y.Q. Wang Y. Teng Y. Zhao Z. Cui Y. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy Science 369 2020 1603 1607 32732280 PMC7574913
- Hou Y.J. Chiba S. Halfmann P. Ehre C. Kuroda M. Dinnon K.H. 3rd Leist S.R. Schäfer A. Nakajima N. Takahashi K. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo Science 370 2020 1464 1468 33184236 PMC7775736
- Hou Y.J. Okuda K. Edwards C.E. Martinez D.R. Asakura T. Dinnon K.H. 3rd Kato T. Lee R.E. Yount B.L. Mascenik T.M. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract Cell 182 2020 429 446.e14 32526206 PMC7250779
- Hu B. Guo H. Zhou P. Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19 Nat. Rev. Microbiol. 19 2021 141 154 33024307 PMC7537588
- Huang Y. Yang C. Xu X.F. Xu W. Liu S.W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Acta Pharmacol. Sin. 41 2020 1141 1149 32747721 PMC7396720
- Johnson B.A. Xie X. Bailey A.L. Kalveram B. Lokugamage K.G. Muruato A. Zou J. Zhang X. Juelich T. Smith J.K. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis Nature 2021 10.1038/s41586-021-03237-4 PMC8175039 33494095 · DOI · Paper page
- Kirchdoerfer R.N. Ward A.B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors Nat. Commun. 10 2019 2342 31138817 PMC6538669
- Kupferschmidt K. Fast-spreading U.K. virus variant raises alarms Science 371 2021 9 10 33384355
- Lakdawala S.S. Menachery V.D. The search for a COVID-19 animal model Science 368 2020 942 943 32467379
- Leist S.R. Dinnon K.H. 3rd Schäfer A. Tse L.V. Okuda K. Hou Y.J. West A. Edwards C.E. Sanders W. Fritch E.J. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard Laboratory Mice Cell 183 2020 1070 1085.e12 33031744 PMC7510428
- Monod M. Blenkinsop A. Xi X. Hebert D. Bershan S. Tietze S. Baguelin M. Bradley V.C. Chen Y. Coupland H. Age groups that sustain resurging COVID-19 epidemics in the United States Science 2021 https://science.sciencemag.org/content/early/2021/02/01/science.abe8372#:∼:text=We%20estimate%20that%20as%20of,20%2D49%20in%20the%20US PMC8101272 33531384
- Nikolakaki E. Giannakouros T. SR/RS motifs as critical determinants of coronavirus life cycle Front. Mol. Biosci. 7 2020 219 32974389 PMC7471607
- Shu Y. Mccauley J. GISAID: global initiative on sharing all influenza data - from vision to reality EURO Surveill 22 2017 30494 28382917 PMC5388101
- Smith E.C. Denison M.R. Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity PLoS Pathog. 9 2013 e1003760 24348241 PMC3857799
- Song H.-D. Tu C.-C. Zhang G.-W. Wang S.-Y. Zheng K. Lei L.-C. Chen Q.-X. Gao Y.-W. Zhou H.-Q. Xiang H. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human Proc. Natl. Acad. Sci. USA 102 2005 2430 2435 15695582 PMC548959
- Su Y.C.F. Bahl J. Joseph U. Butt K.M. Peck H.A. Koay E.S.C. Oon L.L.E. Barr I.G. Vijaykrishna D. Smith G.J.D. Phylodynamics of H1N1/2009 influenza reveals the transition from host adaptation to immune-driven selection Nat. Commun. 6 2015 7952 26245473 PMC4918339
- Sun S. Gu H. Cao L. Chen Q. Yang G. Li R.-T. Fan H. Ye Q. Deng Y.-Q. Song X. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2 bioRxiv 2020 https://www.biorxiv.org/content/10.1101/2020.11.10.377333v1 PMC8476561 34580297 · DOI
- Tortorici M.A. Walls A.C. Lang Y. Wang C. Li Z. Koerhuis D. Boons G.J. Bosch B.J. Rey F.A. De Groot R.J. Veesler D. Structural basis for human coronavirus attachment to sialic acid receptors Nat. Struct. Mol. Biol. 26 2019 481 489 31160783 PMC6554059
- Wang R. Chen J. Gao K. Hozumi Y. Yin C. Wei G. Characterizing SARS-CoV-2 mutations in the United States Res. Sq. 2020 10.21203/rs.3.rs-49671/v1 · DOI
- Watanabe Y. Allen J.D. Wrapp D. Mclellan J.S. Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike Science 369 2020 330 333 32366695 PMC7199903
- Weisblum Y. Schmidt F. Zhang F. Dasilva J. Poston D. Lorenzi J.C. Muecksch F. Rutkowska M. Hoffmann H.H. Michailidis E. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants eLife 9 2020 e61312 33112236 PMC7723407
- Widge A.T. Rouphael N.G. Jackson L.A. Anderson E.J. Roberts P.C. Makhene M. Chappell J.D. Denison M.R. Stevens L.J. Pruijssers A.J. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination N. Engl. J. Med. 384 2021 80 82 33270381 PMC7727324
- Xia H. Shi P.Y. Antagonism of type I interferon by severe acute respiratory syndrome coronavirus 2 J. Interferon Cytokine Res. 40 2020 543 548 33337934 PMC7757701
- Xie X. Liu Y. Liu J. Zhang X. Zou J. Fontes-Garfias C.R. Xia H. Swanson K.A. Cutler M. Cooper D. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera Nature Medicine 2021 10.1038/s41591-021-01270-4 33558724 · DOI · Paper page
- Yurkovetskiy L. Wang X. Pascal K.E. Tomkins-Tinch C. Nyalile T.P. Wang Y. Baum A. Diehl W.E. Dauphin A. Carbone C. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant Cell 183 2020 739 751.e8 32991842 PMC7492024
- Zhou B. Thao T.T.N. Hoffmann D. Taddeo A. Ebert N. Labroussaa F. Pohlmann A. King J. Portmann J. Halwe N.J. SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility bioRxiv 2020 10.1101/2020.10.27.357558 · DOI
- Zhou P. Yang X.-L. Wang X.-G. Hu B. Zhang L. Zhang W. Si H.R. Zhu Y. Li B. Huang C.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 2020 270 273 32015507 PMC7095418
Cited by
Sorted by citations
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · see citing works
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586 · see citing works
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
Edara, V.-V., Pinsky, B. A., Suthar, M. S., Lai, L., Davis-Gardner, M. E., Floyd, K., Flowers, M. W., Wrammert, J., Hussaini, L., Ciric, C. R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107799 · Cited by 328 · see citing works
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224 · see citing works
Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Arora, P., Sidarovich, A., Moldenhauer, A.-S., Winkler, M. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109415 · Cited by 258 · see citing works
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197 · see citing works
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Wong, L.-Y. R., Zheng, J., Wilhelmsen, K., Li, K., Ortiz, M. E., Schnicker, N. J., Thurman, A., Pezzulo, A. A., Szachowicz, P. J., Li, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04630-3 · Cited by 178 · see citing works
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153 · see citing works
- Authors
- Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Bowie State University (US)
- Corresponding author
- Menachery, Vineet D.
- ORCID
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 29
- Issue
- 4
- Pages
- 508-515
- ISSN
- 1931-3128 (ISSN-L)
- PMC
- PMC7919536
- OpenAlex
- W3133745198
- Cited by
- 328
- References
- 18
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 21 · 2023: 54 · 2022: 118 · 2021: 111 · 2020: 1
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 378 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell Host & Microbe (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (cc-by)
- Funders
- National Institute of Allergy and Infectious Diseases
- University of Texas System
- National Institutes of Health (AG049042, AI153602, R24AI120942)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, SARS-CoV-2 variants, viral evolution, spike protein mutations, Alpha variant, Beta variant, P.1, vaccine escape, vaccine efficacy, transmission, variant emergence
- MeSH terms
- SARS-CoV-2, Humans, Mutation, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
